Emtricitabine-d2

Emtricitabine-d2 (BW1592-d2) is deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

Product Specifications

Product Name Alternative

BW1592-d2

UNSPSC

12352005

Target

Endogenous Metabolite; HIV; Isotope-Labeled Compounds; Reverse Transcriptase

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

O=C1N(C=C(C(N)=N1)F)[C@H]2O[C@H](SC2)C([2H])([2H])O

Molecular Formula

C8H8D2FN3O3S

Molecular Weight

249.26

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Faltz M, et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol. 2017 Jan 3. [Epub ahead of print]|[3]Saag MS, et al. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis.?2006 Jan 1;42 (1) :126-31.|[4]Szczech GM, Wang LH, Walsh JP, Reproductive toxicology profile of emtricitabine in mice and rabbits. Reprod Toxicol. 2003 Jan-Feb;17 (1) :95-108.|[5]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12 (4) :682-692.